NEW
Stock Screener with Intrinsic Value
Alnylam Pharmaceuticals, Inc. (ALNY)
Last Price$238.0(1.1%)
Market Cap$30.1B
LTM EPS
($2.62)
EPS growth
(43.2%)
Ben Graham Fair Value
$175.2
Overvalued (Ben Graham formula)
(26.4%)
Stock quality
6/10
Good
ALNY Ben Graham Fair Value
Crunching data... Almost there!
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
ALNY EPS growth & Dividend Yield
Crunching data... Almost there!
ALNY vs Peer Set: Ben Graham Fair Value Comparison
Crunching data... Almost there!
Explore more intrinsic value tools hub for ALNY
Peter Lynch Fair Value
Reverse DCF
Earnings growth model
Earnings Power Value
Discount rate
Relative Value
Intrinsic Value
Margin of safety
DCF value calculator
Peter Lynch charts
Loved by
investors
worldwide
investors
worldwide
10K+
Investors
use our platform
#1
Top value investing hub
with all necessary tools
1K+
Experienced investors
in our community
4.9
Average rating across
all rating platforms
FAQ
What is Alnylam Pharmaceuticals, Inc.'s fair value according to the Ben Graham formula?
As of Sep 30, 2024, Alnylam Pharmaceuticals, Inc.'s fair value using the Ben Graham formula is $175.2 per share. This is calculated using Ben Graham formula, where EPS is ($2.6) and BVPS (Book Value Per Share) is $0.3. The current price of $238.0 suggests Alnylam Pharmaceuticals, Inc. may be overvalued by this conservative metric.
What is Alnylam Pharmaceuticals, Inc. earnings per share (EPS)?
Alnylam Pharmaceuticals, Inc. earnings per share (EPS) for the twelve months ending Sep 30, 2024, was ($2.6), a (43.2%) growth year-over-year.
What is Alnylam Pharmaceuticals, Inc.'s margin of safety based on the Ben Graham analysis?
Alnylam Pharmaceuticals, Inc.'s margin of safety is negative 26.4%, calculated as (Graham Number - Current Price) / Current Price. A negative margin of safety suggests the stock doesn't provide the level of safety Graham typically sought in his investments.